Trial · NCT00256178
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in Triglycerides | Week 24 or Final Visit | |
| Secondary | Change from Baseline in Total Cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in High Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in Very Low Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in apolipoprotein A1 | Week 24 or Final Visit | |
| Secondary | Change from Baseline in apolipoprotein B | Week 24 or Final Visit | |
| Secondary | Change from Baseline in non- High Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol | Week 24 or Final Visit | |
| Secondary | Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B | Week 24 or Final Visit | |
| Secondary | Change from Baseline in high-sensitivity C-reactive protein | Week 24 or Final Visit | |
| Secondary | Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL) | Week 24 or Final Visit | |
| Secondary | Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL) | Week 24 or Final Visit | |
| Secondary | Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL) | Week 24 or Final Visit | |
| Secondary | Best corrected visual acuity | Week 24 or Final Visit | |
| Secondary | Adverse Events | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | |
| Secondary | Clinical Laboratory Tests | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | |
| Secondary | Vital Signs | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | |
| Secondary | 12-lead Electrocardiogram | Timeframe: Weeks 12 and 24 or Final Visit |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00256178/registered